Leptin influences inflammation and immune response. Dosedependent effects of leptin on biomarkers of inflammation have not been studied in vivo, so far. 
Introduction
The increasing prevalence of obesity and its accompanying problems represent a burden of public health magnitude [1] . It is well recognized that human obesity is a state of low-grade inflammation [2] and accumulation of macrophages in adipose tissue results in an upregulation of inflammatory genes [3, 4] . Increased levels of inflammatory cytokines contribute to the morbidity associated with obesity including insulin resistance, diabetes mellitus, and cardiovascular disease [2, 5] .
Various adipose tissue-secreted proteins and yet unidentified factors influence body weight (BW) and metabolic homeostasis [6] . Among those, leptin has been established as one of the most relevant adipokines with circulating levels positively correlating to adipose tissue mass [7, 8] . Leptin exerts its biological actions by binding to its receptor (LepR) [9] . Most immune cells express LepR at their cell surface area which suggests a role for leptin in immune response [10, 11] . Several studies have implicated leptin as an influencer of chronic inflammatory disease states including inflammatory bowel disease, inflammatory nephritis, pelvic endometriosis, nonalcoholic hepatitis, and chronic pulmonary inflammation [12] . Elevated circulating leptin levels in obesity might contribute to the low-grade inflammatory state [6] . Consequently, individuals with obesity are more susceptible to increased risk of developing atherosclerosis [5] . Conversely, reduced levels of leptin such as those found in malnourished individuals have been linked to increased risk of infection and reduced cell-mediated immune responses [13] . Accordingly, genetically obese mice with leptin (ob/ob) or LepR (db/db) deficiency have a number of defects in both cellmediated and humoral immunity [14, 15] .
Taking these studies into consideration, leptin appears to have both pro-and anti-inflammatory effects which might depend on the dose of the adipokine used. However, to the best of our knowledge dose-dependent effects of leptin on proinflammatory markers such as interleukin (IL)-6 and monocyte chemoattractant protein (MCP)-1 have not been assessed so far. We hypothesized that treatment with three increasing fixed doses of recombinant leptin, within subphysiological doses, that is, doses not sufficient to normalize body weight (BW; 0.1 and 0.5 mg/kg BW/day) to physiological doses, that is, doses sufficient to normalize BW (3.0 mg/kg BW/day), leads to potent antiinflammatory effects and decreased atherosclerotic lesions in female leptin-deficient LDLR −/− ;ob/ob mice.
Materials and methods

Animal care
The local ethics committee (Landesdirektion Sachsen, Leipzig) of the state of Saxony approved the protocol of all animal experiments (approval no. TVV37/12). Breeding and husbandry of homozygous female LDLR knockout and leptin-deficient (LDLR −/− ;ob/ob) mice was done in our local animal facility, the Medical Experimental Center of the University of Leipzig. All mice were maintained in a room under pathogen-free conditions with controlled 21 AE 1 C on a 12:12 h light/dark cycle (6 AM/6 PM). Water and chow pellet diet (V1534 from Sniff, Soest, Germany) were provided ad libitum until the age of 4 weeks.
Animal treatment
Starting at the age of 4 weeks, LDLR −/− ;ob/ob female mice (n ≥ 17 per group) were fed ad libitum with an atherogenic semisynthetic Clinton/Cybulsky diet (Sniff, Soest, Germany). At 8 weeks of age, BW-matched mice were separated into four groups and treated daily over a period of 12 weeks i.p. with saline or increasing concentrations of recombinant mouse leptin (0.1 mg/kg BW, 0.5 mg/kg BW, and 3.0 mg/kg BW) (R&D Systems, Wiesbaden-Nordenstadt, Germany). At the end of the treatment period, mice were fasted overnight and plasma samples were obtained. Subcutaneous (sAT), epididymal (epiAT), intrascapular brown (iBAT), perirenal (perirAT), and pericardial (pericAT) adipose tissue was removed and placed in either formalin or was snap frozen. Basic characteristics of the salineand leptin-treated groups are summarized in Supplementary  Table 1 . 
Immunoassays
Plasma concentrations of IL-6 were analyzed using a Milliplex magnetic bead-based assay by Luminex technology (MAGPIX ® System; Millipore Corp., St. Charles, MO) according to the manufacturer's protocol. MCP-1 plasma levels were analyzed by Enzyme-linked Immunosorbent assay (R&D Systems, Minneapolis, MN).
Quantitative real-time RT-PCR analysis
Il-6 and Mcp-1 mRNA expression was determined relative to 36B4 by quantitative real-time RT-PCR in a fluorescent temperature cycler (Roche, Heidelberg, Germany) as described previously [16, 17] . Primers sequences are summarized in Supplementary Table 2 .
Immunohistochemistry
Adipose tissue macrophages were determined by immunohistochemistry using specific Mac2 antibody (clone M3/38, Cedarlane, Burlington, Ontario, Canada) at 1:800 dilution. Immunohistochemistry was performed using 5 μm thick formalin-fixed, paraffin-embedded epiAT sections. Brown immunoperoxidase staining was developed using a DAB chromogen (Agilent, Waldbronn, Germany) and counterstained with hematoxylin (blue). All slides were photographed and analyzed manually by two independent evaluators in a blinded fashion using Zeiss Axioskop microscope (Carl Zeiss Microscopy GmbH, Jena, Germany), Cell F image analysis (Olympus, Hamburg, Germany), and Fiji (https://imagej. net/Fiji).
Quantification and characterization of atherosclerotic lesions
The extent of atherosclerosis in the aortic root was determined in a blinded fashion as recently described [18, 19] . Macrophage content of aortic root lesions was determined by immunohistochemistry using specific CD68-antibodies (Bio-Rad AbD Serotec GmbH, Puchheim, Germany) as well as IL-6 and MCP-1 antibodies (Abcam, Cambridge, UK). All lesions were photographed and analyzed using AxioVision Rel 4.8, KS400 image analysis, and ZEN 2012 blue edition 1.1.1.0 (all Carl Zeiss Microscopy GmbH, Jena, Germany).
Data analysis and statistics
Data sets were analyzed using GraphPad Prism 6 (GraphPad Software, San Diego, CA). Values are presented as mean AE standard error of the mean (SEM). Statistical significance was assessed as indicated in the figure legends. A P <0.05 was considered as statistically significant in all analyses.
Results
Circulating IL-6 and MCP-1 are decreased by leptin treatment
Leptin decreased BW in all treatment groups as compared to saline controls ( Supplementary Fig. 1 ). At 20 weeks of age, LDLR −/− ;ob/ob mice treated with 3.0 mg/kg BW/day had similar Differences were assessed by one-way ANOVA corrected by Bonferroni-Holm. * Indicates P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
weight (physiological leptin dose) whereas the groups treated with 0.1 and 0.5 mg/kg BW/day remained heavier (subphysiological leptin dose) as compared to non-leptin-deficient LDLR −/− animals (Supplemental Fig. 1 ). Plasma IL-6 levels were significantly decreased by leptin treatment from 22.7 pg/ml (saline control) to 6.1 pg/ml (0.1 mg/kg BW/day; P < 0.01), 4.9 pg/ml (0.5 mg/kg BW/day; P < 0.001), and 6.6 pg/ml (3.0 mg/kg BW/day; P < 0.01), respectively (Fig. 1A) . Recombinant leptin treatment decreased MCP-1 plasma concentrations significantly in a dose-dependent fashion from 104.4 pg/ml (saline control) to 60.5 pg/ml (3.0 mg/kg BW/day; P < 0.01; Fig. 1B ).
Il-6 and Mcp-1 mRNA expression in adipose tissue are decreased by leptin treatment
Leptin-mediated decrease in circulating IL-6 was accompanied by downregulated mRNA expression of the cytokine in sAT ( Fig. 2A) , epiAT (Fig. 2C) , iBAT (Fig. 2E) , perirAT (Fig. 2G) , and pericAT (Fig. 2I) . Similarly, mRNA expression of the proinflammatory cytokine Mcp-1 was significantly down-regulated by leptin treatment in sAT (Fig. 2B) , epiAT (Fig. 2D) , iBAT (Fig. 2F) , perirAT (Fig. 2H) , and pericAT (Fig. 2J ).
Crown-like structure (CLS) density is reduced by leptin treatment in epiAT
Immunohistochemistry further identified cell types involved in the inflammatory changes in epiAT. CLS per field were significantly decreased from 1.1 in epiAT from saline treated LDLR −/− ;ob/ob female mice to 0.2 in leptin-treated animals (3.0 mg/kg BW/day; P < 0.01; Fig. 3 ).
Leptin dose-dependently reduces atherosclerotic lesion size but not IL-6-and MCP-1-positive plaque area relative to whole plaque area
Similar to published data from our group in male animals [20] , leptin dose-dependently decreased lesion size in the aortic root (Fig. 4A ) in female LDLR −/− ;ob/ob mice as compared to saline with most pronounced effects observed at 3.0 mg/kg BW/day leptin. However, there was no significant difference in CD68-, IL-6-, and MCP-1-positive plaque area relative to whole plaque area between the different treatment groups (Fig. 4B ).
Discussion
In the current study, we provide first evidence that leptin administration within the subphysiological to physiological range decreases circulating levels of the pro-inflammatory cytokines IL-6 and MCP-1. IL-6 is a cellular cytokine associated with the recruitment of macrophages and monocytes into atherosclerotic plaques [21] . Furthermore, IL-6 accelerates atherosclerosis in both apolipoprotein (Apo) E-deficient and wild-type mice [22, 23] . MCP-1 plays a fundamental role in monocyte recruitment [24] and increased MCP-1 expression is detected in atherosclerotic lesions of both humans and animals but not in normal arteries [25] . In agreement with proatherogenic effects of IL-6 and MCP-1, leptin within the subphysiological to physiological range dose-dependently decreases atherosclerotic lesion area in female leptin-deficient LDLR −/− ;ob/ob mice in this study similar to recent findings from our group in male animals [20] . These published findings and our present data are in agreement with the hypothesis that the anti-atherogenic effects of subphysiological to physiological leptin doses are mediated in part by reduction of both pro-inflammatory IL-6 and MCP-1. However, there was no significant difference in IL-6-and MCP-1-positive plaque area relative to whole plaque area. Furthermore, other mechanisms including a reduction of hypercholesterolemia and adiponectin upregulation (Supplemental Table 1 and [20, 26] ), as well as other potential factors [27] , probably also contribute to the beneficial effects of leptin on insulin resistance and atherogenesis. It needs to be pointed out that proinflammatory effects of supraphysiological leptin doses have been shown. Thus, incubation of resting peripheral blood mononuclear cells with high dose leptin (250 ng/ml) induces rapid mRNA expression of tumor necrosis factor (tnf )-α and il-6 and secretion of TNF-α and IL-6 by monocytes [28] . High leptin concentrations are also positively associated with levels of MCP-1 [29] and other cardiovascular risk factors such as circulating fibrinogen [30] . Based on these data, it is tempting to speculate that leptin´s effects on inflammation are dosedependent with subphysiological to physiological doses showing anti-inflammatory effects whereas high doses are proinflammatory. Clearly, more work is needed to better elucidate mechanisms for pro-and anti-inflammatory effects of the adipokine.
In the current study, we demonstrate that leptin within the subphysiological and physiological range decreases Il-6 and Mcp-1 mRNA expression in all adipose tissue depots examined, that is, sAT, epiAT, iBAT, perirAT, and pericAT. Western blotting analysis for IL-6 and MCP-1 protein synthesis in adipose tissue depots did not yield specific bands for both proteins (data not shown). Furthermore, number of CLS is reduced in epiAT upon leptin administrations. These findings support the notion that subphysiological to physiological leptin doses counteracts adipose tissue inflammation and that decreases in local inflammatory response in adipose tissue might contribute to decreased circulating levels of IL-6 and MCP-1. However, it needs to be pointed out that the effects observed do not necessarily depend directly on leptin only and other factors might be also involved [31] . Furthermore, within adipose tissue counter-regulatory effects might take place, for example, inflammation is associated with a decrease of lipogenic factors in omental fat [32] and gene expression of the main lipogenic enzymes is downregulated in visceral adipose tissue of obese individuals [33] .
Taken together, leptin administration within the subphysiological to physiological range diminishes circulating proinflammatory IL-6 and MCP-1. Reduction of Il-6 and Mcp-1 gene expression in adipose tissue, as well as decreased adipose tissue macrophage infiltration might contribute.
